For the second time, Adamis Pharmaceuticals Corp. has received a complete response letter from the US Food and Drug Administration for Zimhi (naloxone), its drug to treat opioid overdoses – and for the second time it was related to quality issues. Adamis has a history over the years of receiving multiple – though not necessarily interrelated – CRLs for its injectable products, and the latest one comes at a challenging time for the company.
Adamis Gets Another CRL For Opioid Overdose-Reversal Drug
Adamis got its second complete response letter for Zimhi. While not apparently related to the first, it may complicate the company's outlook following a lackluster quarter.
More from New Products
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The German group is paying $3.9bn to get hold of the US firm and its two approved products.
• By
Akeso’s penpulimab will be the second to hit the US market for nasopharyngeal carcinoma, but the first to win FDA approval for the indication based on clinical findings in US patients.